|
|
 |
|
| Overview |
| The antibody is suitable for the identification and enumeration of CD158a (KIR2DL2)+ and CD158h (KIR2DS1)+ cells by flow cytometry and fluorescence microscopy. The family of killer immunoglobulin-like receptors (KIR) contributes to the regulation of NK cell–mediated cytotoxicity. |
| Details |
Background information
Clone 11PB6, also referred to as EB6, recognizes CD158a (KIR2DL1) and CD158h (KIR2DS1), two members of the killer immunoglobulin-like receptor (KIR) family expressed on CD56dimCD16+ natural killer (NK) cells and CD8+ T cells.
Recent findings also showed reactivity of 11PB6 with KIR2DL3*005.1
CD158a (KIR2DL1) is involved in the transduction of an inhibitory signal whereas CD158h (KIR2DS1) is an activating receptor. The ligands of CD158a (KIR2DL1) are HLA-Cw4 and related molecules. |
| Clone | Isotype |
| 11PB6 | Mouse IgG1 |
| |
| Figure 1 |
| Human PBMCs were stained with CD158a/h (KIR2DL1/DS1)-FITC (A), -PE (B), -APC (C), or VioBlue (D) and CD56-PE or -APC, respectively. Cells stained with CD158a/h (KIR2DL1/DS1)-Biotin were stained with Anti-Biotin-APC in addition (E). Cells were analyzed by flow cytometry using the MACSQuant® Analyzer. |
| A |
 |
| B |
 |
| C |
 |
| D |
 |
| E |
 |
|
|
|
|
| Products |
| CD158a/h (KIR2DL1/DS1)-FITC, human |
- for 100 tests (1)
Download datasheet
130-092-811
|
| CD158a/h (KIR2DL1/DS1)-PE, human |
- for 100 tests (1)
Download datasheet
130-092-684
|
| CD158a/h (KIR2DL1/DS1)-APC, human |
- for 100 tests (1)
Download datasheet
130-092-685
|
| CD158a/h (KIR2DL1/DS1)-VioBlue, human |
- for 100 tests (1)
Download datasheet
130-095-233
|
| CD158a/h (KIR2DL1/DS1)-Biotin, human |
- for 100 tests (2)
Download datasheet
130-092-683
|
| CD158a/h (KIR2DL1/DS1) pure, human |
- 100 µg in 1 mL
Download datasheet
130-092-682
|
| (1) One test corresponds to fluorescent labeling of up to 107 cells in a total volume of 100 µL. |
| (2) One test corresponds to labeling of up to 107 cells in a total volume of 100 µL. |
|
| References |
| 1. Falco M. et al. (2010) J. Immunol. 185: 433–441. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
